[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Global Patent Index - EP 2012824 A4

EP 2012824 A4 20100616 - USES AND COMPOSITIONS FOR TREATMENT OF PSORIASIS

Title (en)

USES AND COMPOSITIONS FOR TREATMENT OF PSORIASIS

Title (de)

ANWENDUNGEN UND ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON SCHUPPENFLECHTE

Title (fr)

UTILISATION ET COMPOSITIONS POUR LE TRAITEMENT DU PSORIASIS

Publication

EP 2012824 A4 20100616 (EN)

Application

EP 07755413 A 20070410

Priority

  • US 2007009131 W 20070410
  • US 79090906 P 20060410
  • US 80977006 P 20060530
  • US 81548906 P 20060620
  • US 81789106 P 20060629
  • US 84012206 P 20060825
  • US 89926207 P 20070202
  • US 90968307 P 20070402

Abstract (en)

[origin: WO2007120823A2] The invention provides methods, uses and compositions for the treatment of psoriasis. The invention describes methods and uses for treating psoriasis, wherein a TNFa inhibitor, such as a human TNFa antibody, or antigen-binding portion thereof, is used to treat psoriasis in a subject. Also described are methods for determining the efficacy of a TNFa inhibitor for treatment psoriasis in a subject.

IPC 8 full level

A61K 39/395 (2006.01); C07K 16/00 (2006.01); C07K 16/18 (2006.01); C07K 16/24 (2006.01)

CPC (source: EP)

C07K 16/241 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/21 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01)

Citation (search report)

  • [X] WO 2005110452 A2 20051124 - ABBOTT BIOTECH LTD, et al
  • [X] PATEL TORAL ET AL: "Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis", DERMATOLOGIC THERAPY, MUNKSGAARD, COPENHAGEN, DK LNKD- DOI:10.1111/J.1396-0296.2004.04045.X, vol. 17, no. 5, 1 January 2004 (2004-01-01), pages 427 - 431, XP002477489, ISSN: 1396-0296
  • [X] KOO J ET AL: "Update on the mechanisms and efficacy of biological therapies for psoriasis", JOURNAL OF DERMATOLOGICAL SCIENCE, ELSEVIER SCIENCE PUBLISHERS, SHANNON, IR LNKD- DOI:10.1016/J.JDERMSCI.2005.01.011, vol. 38, no. 2, 1 May 2005 (2005-05-01), pages 75 - 87, XP025305570, ISSN: 0923-1811, [retrieved on 20050501]
  • [X] WINTERFIELD L S ET AL: "Psoriasis treatment: current and emerging directed therapies.", ANNALS OF THE RHEUMATIC DISEASES MAR 2005 LNKD- PUBMED:15708946, vol. 64 Suppl 2, March 2005 (2005-03-01), pages II87 - II90 ; DI, XP002580559, ISSN: 0003-4967
  • [X] SAINI RITU ET AL: "Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus.", CURRENT PHARMACEUTICAL DESIGN 2005 LNKD- PUBMED:15638763, vol. 11, no. 2, 2005, pages 273 - 280, XP009132703, ISSN: 1381-6128
  • [A] CHEN DM ET AL.: "ADALIMUMAB EFFICACY AND SAFETY IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: PRELIMINARY FINDINGS FROM A 12-WEEK DOSE-RANGING TRIAL", SUPPLEMENT TO THE JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, vol. 50, no. 3, P2, March 2004 (2004-03-01), pages P1, XP002580561
  • [A] SLADDEN M J ET AL: "Extensive plaque psoriasis successfully treated with adalimumab (Humira).", THE BRITISH JOURNAL OF DERMATOLOGY MAY 2005 LNKD- PUBMED:15888191, vol. 152, no. 5, May 2005 (2005-05-01), pages 1091 - 1092, XP002580562, ISSN: 0007-0963
  • [A] CHEW A-L ET AL: "Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab.", THE BRITISH JOURNAL OF DERMATOLOGY AUG 2004 LNKD- PUBMED:15327561, vol. 151, no. 2, August 2004 (2004-08-01), pages 492 - 496, XP002580563, ISSN: 0007-0963
  • [A] GORDON KENNETH B ET AL: "Definitions of measures of effect duration for psoriasis treatments.", ARCHIVES OF DERMATOLOGY JAN 2005 LNKD- PUBMED:15655149, vol. 141, no. 1, January 2005 (2005-01-01), pages 82 - 84, XP009132702, ISSN: 0003-987X
  • See references of WO 2007120823A2

Citation (examination)

  • "Adalimumab efficacy and safety results in patients with moderate to severe chronic plaque psoriasis with and without psoriatic arthritis", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, C.V. MOSBY, ST. LOUIS, MO, US, vol. 52, no. 3, 1 March 2005 (2005-03-01), pages P174, XP004840889, ISSN: 0190-9622
  • "Long-term safety and efficayc of adalimumab in the treatment of moderate to severe chronic plaque psoriasis", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, C.V. MOSBY, ST. LOUIS, MO, US, vol. 52, no. 3, 1 March 2005 (2005-03-01), pages P8, XP002720516, ISSN: 0190-9622

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

Designated extension state (EPC)

BA HR MK RS

DOCDB simple family (publication)

WO 2007120823 A2 20071025; WO 2007120823 A3 20081002; EP 2012824 A2 20090114; EP 2012824 A4 20100616

DOCDB simple family (application)

US 2007009131 W 20070410; EP 07755413 A 20070410